The EuroSIDA study is a prospective observational cohort study of more than 18791 patients followed in 108 hospitals in 34 European countries plus Israel and Argentina. The main objective of the study is to assess the impact of antiretroviral drugs on the outcome of the general population of HIV-infected patients living in Europe.
Primary support for EuroSIDA is provided by the European Commission BIOMED 1 (CT94-1637), BIOMED 2 (CT97-2713), the 5th Framework (QLK2-2000-00773), the 6th Framework (LSHP-CT-2006-018632), and the 7th Framework (FP7/2007-2013, EuroCoord n° 260694) programmes. Current support also includes unrestricted grants by Bristol-Myers Squibb, Janssen R&D, Merck and Co. Inc., Pfizer Inc., GlaxoSmithKline LLC. The participation of centres from Switzerland was supported by The Swiss National Science Foundation (Grant 108787).
Co-Project Leaders: Ole Kirk and Amanda Mocroft
Data Manager: Rikke Salbøl Brandt firstname.lastname@example.org
Coordinating Centre Staff:
Kamilla Grønborg Laut email@example.com
Charlotte Matthews firstname.lastname@example.org
Jette Nielsen email@example.com
Annette Fischer firstname.lastname@example.org
Ane Bojesen email@example.com
Updated: 08 Apr 2014